The novel immunotherapeutic molecule T11TS modulates glioma-induced changes of key components of the immunological synapse in favor of T cell activation and glioma abrogation

作者：Chaudhuri Suhnrita; Singh Manoj Kumar; Bhattacharya Debanjan; Acharya Sagar; Chatterjee Sirshendu; Kumar Pankaj; Bhattacharjee Pushpak; Basu Anjan Kumar; Sa Gaurisankar; Das Tanya; Ghosh Tushar Kanti; Chaudhuri Swapna

来源：Journal of Neuro-Oncology, 2014, 120(1): 19-31.

DOI：10.1007/s11060-014-1528-9

• T-cell
• Antigen presenting cell (APC)
• Immunological synapse
• T11TS
• Glioma

T-cell-mediated immune responses are typically low in conditions of malignant glioma which has been known to cause marked immunesuppression and dysregulate major T-cell signaling molecules. Thus, T-cell-based immunotherapies are currently in vogue in the treatment of malignant glioma. The novel glycopeptide, T11TS/S-LFA-3/S-CD58 has previously been shown by our group to be highly efficacious in glioma abrogation in in vivo and in vitro conditions. This glycopeptide ligands to the costimulatory CD2 molecule on T-cells, causing profound immune stimulation leading to glioma abrogation, suggesting probable involvement of T11TS in modulation of the T-cell signaling pathway. The present study offers a multi-targeted approach towards repair of some of the key components of the immunological synapse at the T-cell-APC interface and is therefore the first of its kind to offer a holistic model of restoration of immunological synapse components so as to trigger T-cells towards activation against glioma. The study thus indicates that the totally dysregulated molecular events at the immunological synapse in glioma are restored back to normal levels with the administration of T11TS, which finally culminates in glioma abrogation. The present study thus delineates an important T-cell signaling approach whereby T11TS acts as an anti-neoplastic agent, thus helping to chart out newer avenues in the fight against gliomas.

• 出版日期2014-10